Sprycel
Author: Hardik Patel
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka) is an oral targeted therapy that inhibits several tyrosine kinases including BCR-ABL, c-KIT, and the Src family kinases. The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease. The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.
TABLE OF CONTENTS
4 Product Profiles
4 Sprycel : Chronic myeloid leukemia (CML)
16 Sprycel : Acute lymphoblastic leukemia (ALL)
LIST OF FIGURES
10 Figure 1: Sprycel for CML – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Sprycel for CML
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Sprycel for CML
19 Figure 4: Sprycel – SWOT analysis in acute lymphoblastic leukemia
20 Figure 5: Datamonitor Healthcare’s drug assessment summary for Sprycel in acute lymphoblastic leukemia
21 Figure 6: Datamonitor Healthcare’s drug assessment summary for Sprycel in acute lymphoblastic leukemia
LIST OF TABLES
5 Table 1: Sprycel drug profile
7 Table 2: Sprycel pivotal trial data in CML
9 Table 3: Sprycel ongoing late-phase trial in CML
13 Table 4: Sprycel and Tasigna trial data in first-line CML
17 Table 5: Sprycel drug profile
18 Table 6: Overview of pivotal trial data for Sprycel in acute lymphoblastic leukemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare Strategy: Gene Therapy Pipeline and Portfolio Analys... 
Sign up to the